ADAMTS13 and Cirrhosis: In cirrhotic samples, T-TAS 01 assays were also performed after adding PMNPs to evaluate their hemostatic efficacy.<h4>Results</h4>Patients with cirrhosis had significantly lower platelet counts (97 vs 218 G/L, <i>P</i> < .0001), higher VWF antigen levels (310% vs 119%, <i>P</i> < .0001), and reduced ADAMTS13 activity (77% vs 100%, <i>P</i> < .01) compared with controls.